Skip to main content

Remote Job Finders (RJF)

Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’

After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile cardiovascular flops to six over nine weeks.

Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic

Moonwalk Biosciences plans to shepherd its lead obesity asset into first-in-human trials in late 2027. In preclinical studies, MW101 has demonstrated weight loss and fat reduction while maintaining muscle mass.
Scroll to top